- Home
- MYFW vs VCRE Comparison
MYFW vs VCRE Comparison
Compare MYFW & VCRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | MYFW | VCRE |
|---|---|---|
| Founded | 2002 | 2000 |
| Country | United States | Sweden |
| Employees | N/A | N/A |
| Industry | Major Banks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 312.1M | 271.7M |
| IPO Year | 2018 | 2026 |
Fundamental Metrics
Financial Performance| Metric | MYFW | VCRE |
|---|---|---|
| Price | $29.52 | $8.98 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | ★ $32.67 | $29.16 |
| AVG Volume (30 Days) | ★ 31.1K | 25.3K |
| Earning Date | 10-22-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 54.02 | N/A |
| EPS | ★ 1.20 | N/A |
| Revenue | ★ $96,914,000.00 | N/A |
| Revenue This Year | $12.79 | $101.29 |
| Revenue Next Year | $7.98 | $481.15 |
| P/E Ratio | $24.55 | ★ N/A |
| Revenue Growth | ★ 7.60 | N/A |
| 52 Week Low | $22.00 | $7.88 |
| 52 Week High | $34.36 | $14.01 |
Technical Indicators
Market Signals| Indicator | MYFW | VCRE |
|---|---|---|
| Relative Strength Index (RSI) | 39.60 | 40.94 |
| Support Level | $27.71 | $8.34 |
| Resistance Level | $30.00 | $12.08 |
| Average True Range (ATR) | 0.58 | 0.85 |
| MACD | -0.04 | 0.03 |
| Stochastic Oscillator | 34.78 | 26.70 |
Price Performance
Historical ComparisonAbout MYFW First Western Financial Inc.
First Western Financial Inc is a financial holding company that provides a fully integrated suite of wealth management services on its private trust bank platform, which includes a comprehensive selection of deposit, loan, trust, wealth planning, and investment management products and services. The company has two operating segments; The Wealth Management segment consists of operations relative to the Company's fully integrated wealth management products and services, and The Mortgage segment consists of operations relative to the Company's residential mortgage service offerings. The bank derives its majority revenue from the wealth management segment.
About VCRE Vicore Pharma Holding AB American Depositary Shares
Vicore Pharma Holding AB is a clinical-stage biopharmaceutical company developing a new class of disease-modifying therapies for respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). Its main program, buloxibutid, is an oral angiotensin II type 2 receptor agonist that has received Orphan Drug and Fast Track designation from the U.S. Food and Drug Administration and is currently being evaluated in the 52-week Phase 2b ASPIRE trial in IPF. Currently, Vicore is operating mainly in Sweden.